FDA label 2acd70fc-27be-4881-afff-d15fe43cef0b
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 3d83fdf7-78f7-4ea0-97a9-e7434c82067d
- SPL ID
- 2acd70fc-27be-4881-afff-d15fe43cef0b
- Version
- 4
- Effective date
- 2019-06-07
- Source export date
- 2026-09-28
- Source partition
- 9
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0009-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/6784607726c827491ceaeab30d843632e0660ee8008c535197be5ed9e1e52201/drug-label-0009-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:00:40
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 2acd70fc-27be-4881-afff-d15fe43cef0b | id | |
| spl set id | 3d83fdf7-78f7-4ea0-97a9-e7434c82067d | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS The contents of the vial of INDICLOR Indium In-111 Chloride solution are intended only to be used as an ingredient for radiolabeling ProstaScint used for in vivo diagnostic imaging procedures and for radiolabeling Zevalin in preparations used for radioimmunotherapy procedures. Indiclor is not to be administered directly to humans.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Please refer to the package insert for ProstaScint or Zevalin for this information on the final drug product.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.